Assay News and Research

RSS

New technology gives tool to examine membrane proteins in natural environment of human cell

Scientists have a better way to study human proteins - large molecules that are part of every cell in the body - thanks to a new technology developed by University of Toronto researchers.

25 Mar 2014

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Noninvasive tumour genotyping using cell-free plasma DNA analysis is feasible, say US researchers who believe the technique will aid patient diagnosis and monitoring.

24 Mar 2014

ChromaTrap™ Chromatin Immunoprecipitation technology receives positive commentary in published paper

Porvair Sciences reports on positive commentary by researchers in published papers citing how using the fast, sensitive ChromaTrap™ Chromatin Immunoprecipitation (ChIP) technology has benefited their research.

From Chromatrap® - Porvair Sciences Ltd 18 Mar 2014

Trovagene reports net loss of $1 million for fourth quarter 2013

Trovagene, Inc., a developer of cell-free molecular diagnostics, today reported its financial results for the quarter and the year ended December 31, 2013.

18 Mar 2014

UC Davis MIND Institute named Intellectual and Developmental Disabilities Research Center

The UC Davis MIND Institute has been named an Intellectual and Developmental Disabilities Research Center, through a prestigious grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health - a distinction held by only a handful of neurodevelopmental centers nationwide committed to the diagnosis, prevention, treatment and amelioration of developmental disorders such as autism, fragile X syndrome and Down syndrome.

14 Mar 2014

Venaxis' APPY1 Test for appendicitis shows positive results in pivotal U.S. study

Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced positive top-line results from its pivotal U.S. study.

14 Mar 2014

Blocking function of enzyme slows spread of pancreatic cancer, say researchers

A research team from Imperial College London has shown that blocking the function of an enzyme known as Hhat slows the growth and spread of pancreatic cancer, by preventing a protein called Hedgehog from stimulating nearby normal cells to help the cancer.

13 Mar 2014

Innovative study uses pharmacogenomic test to treat patients with psychotic disorders

ValueOptions, Inc. a health improvement company specializing in mental and emotional well-being and recovery, and Genomind, a personalized medicine company, today announced an innovative study that uses pharmacogenomic testing to treat patients diagnosed with psychotic disorders, including schizophrenia and bipolar disorder.

11 Mar 2014

Promethera Biosciences, EMD Millipore partner to develop ready-to-use microfluidic perfusion liver assay

Promethera Biosciences, a company that develops innovative therapies for the treatment of liver diseases, today announces a collaboration with EMD Millipore to develop an improved ready-to-use microfluidic perfusion liver assay. This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism.

11 Mar 2014

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Illumina, Inc. and WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

From Illumina, Inc. 10 Mar 2014

Agendia co-founder to be honored with 2014 European Union Prize for Women Innovators

Agendia co-founder Laura van 't Veer, Ph.D., will receive a 2014 European Union Prize for Women Innovators in ceremonies next Monday. Dr. van 't Veer, of the Netherlands, is the inventor of Agendia's MammaPrint® breast cancer test.

7 Mar 2014

Boston Heart Diagnostics announces commercial launch of FDA-cleared MPO test

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.

6 Mar 2014

ASTRO white paper recommends specific guidance to follow in the delivery of HDR brachytherapy

The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.

6 Mar 2014

RainDance Technologies closes $16.5 million Series E financing round

RainDance Technologies, Inc., an innovative genomics tools company making molecular testing of complex diseases more standardized and readily available, today announced that it has closed a $16.5 million Series E financing round extension. New investors include GE Ventures and Northgate Capital; all existing financial investors also participated in this round of financing.

3 Mar 2014

Google Glass app helps researchers track spread of diseases around the world

The much-talked-about Google Glass - the eyewear with computer capabilities - could potentially save lives, especially in isolated or far-flung locations, say scientists. They are reporting development of a Google Glass app that takes a picture of a diagnostic test strip and sends the data to computers, which then rapidly beam back a diagnostic report to the user.

3 Mar 2014

Plasma microRNA test boosts lung cancer screening

The ability to screen for lung cancer is improved by the development of a plasma 24-microRNA signature classifier, research suggests.

28 Feb 2014

Engineers develop paper test that could improve diagnosis rates for cancer

Cancer rates in developing nations have climbed sharply in recent years, and now account for 70 percent of cancer mortality worldwide. Early detection has been proven to improve outcomes, but screening approaches such as mammograms and colonoscopy, used in the developed world, are too costly to be implemented in settings with little medical infrastructure.

26 Feb 2014

Researchers find that single genetic mutation causes resistance to DDT and pyrethroids

Researchers from LSTM have found that a single genetic mutation causes resistance to DDT and pyrethroids (an insecticide class used in mosquito nets). With the continuing rise of resistance the research, published in the journal Genome Biology, is key as scientists say that this knowledge could help improve malaria control strategies.

25 Feb 2014

Support for progranulin role in bipolar disorder

Researchers have found reduced levels of plasma progranulin in patients with bipolar disorder, strengthening evidence for its possible role as a biomarker for the condition.

20 Feb 2014

Researchers develop screening assay that quickly assesses nearly 1,500 compounds' effect on estrogen

A team of researchers at City of Hope has developed a screening assay that can quickly assess up to 1,536 compounds' effect on estrogen activity in the body. The test can also evaluate whether chemicals act as inhibitors of aromatase, an enzyme linked to breast cancer that converts androgen to estrogen.